Biotech 2050 Podcast6 Joulu 2023

A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology

Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in late 2022. Sean provides an update on all the exciting things that have happened at Olema since then, including an update on their lead product candidate. Sean reflects on navigating the challenging biotech market environment over the past year, making careful spending decisions, and raising significant capital to extend Olema’s runway. He also offers advice to first-time CEOs on building a strong support network to guide company growth. Biography: Dr. Bohen has served as Chief Executive Officer of Olema Oncology and a member of the Board of Directors since September 2020. He is also a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He has extensive oncology drug development experience, having served as Executive Vice President, Global Medicines Development, and Chief Medical Officer at AstraZeneca PLC. Before that, he held a number of senior leadership roles at Genentech, Inc., including Senior Vice President, Early Development, Genentech Research and Early Development. Prior to Genentech, he was a Clinical Instructor in Oncology at Stanford University School of Medicine; a research associate at the Howard Hughes Medical Institute; and a postdoctoral fellow at the National Cancer Institute (NCI). Dr. Bohen received a B.S. in bacteriology from the University of Wisconsin-Madison, and a Ph.D. in biochemistry and biophysics and an M.D. from the University of California, San Francisco.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(261)

Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients

Synopsis: While biotech is increasingly measured by clinical milestones and financial outcomes, Rahul Chaturvedi welcomes two leaders who argue that true success begins and ends with patients. In th...

10 Kesä 41min

Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision

Synopsis: At the intersection of personal mission and biotech leadership, Rahul Chaturvedi sits down with Catherine Owen Adams, CEO of Acadia Pharmaceuticals, for a deeply personal and strategically...

13 Touko 33min

Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Co...

16 Huhti 23min

Adial CEO Cary Claiborne on Treating Alcohol Addiction with Genetics

Synopsis: Addiction is often misunderstood as a failure of willpower—but emerging science increasingly shows it may be deeply rooted in biology. In this episode of Biotech 2050, recorded during JPM...

6 Maalis 14min

Sheila Gujrathi, MD on Leadership, Biotech Innovation & The Mirror Effect for Women Leaders

Synopsis: This episode is proudly sponsored by Quartzy. Physician-scientist, biotech founder, and leadership advocate Sheila Gujrathi, MD joins Rahul Chaturvedi on the Biotech 2050 Podcast for a po...

5 Maalis 39min

Fred Aslan, Artiva CEO, on Cell Therapy’s Next Wave, RA Trials & Scalable NK Platforms

Synopsis: At the heart of JPM 2026’s biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could ...

11 Helmi 25min

Michelle Werner, CEO of Alltrna, on tRNA Platforms, Rare Disease & Drug Innovation

Synopsis: At JPM 2026 in San Francisco, Alok Tayi welcomes Michelle Werner, CEO of Alltrna, to Biotech 2050 for a powerful conversation at the intersection of personal mission, platform biology, and...

10 Helmi 26min

Brian Hilberdink on Boehringer’s U.S. Growth, AI & Pharma’s Next Frontier

Synopsis: From managing a theme park in Canada to leading the U.S. business of one of the world’s largest privately held pharma companies, Brian Hilberdink’s journey is anything but conventional. Li...

28 Tammi 21min